You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites.
Cancel Ok

Etrasimod


Etrasimod

A drug candidate for the treatment of immune-mediated and inflammatory diseases. Etrasimod is an investigational, once-daily, oral, selective S1P receptor modulator designed to partially and reversibly reduce lymphocyte levels at sites of inflammation, while maintaining components of immune function.

CLINICAL TRIALS

  • RISE UP AGAINST ULCERATIVE COLITIS (UC)
    A worldwide, Phase 3 clinical program evaluating etrasimod—an oral, selective, sphingosine 1 phosphate (S1P) receptor modulator—for the treatment of moderately to severely active ulcerative colitis.

    ClinicalTrials.gov: NCT03945188, NCT03996369, NCT03950232
    Patient Trial Site
  • ADDRESSING THE ROOT OF CROHN’S DISEASE (CD)
    CULTIVATE is a Phase 2/3 clinical trial evaluating the efficacy and safety of once-daily, oral etrasimod in patients with moderately to severely active Crohn’s disease (CD).

    ClinicalTrials.gov: NCT04173273
    Patient Trial Site
  • BRINGING THE FIGHT TO UC
    A Phase 2, 52-week induction and maintenance study evaluating the safety and efficacy of once-daily, oral etrasimod in patients with moderately active UC. Patients with disease activity insufficient to qualify for the ELEVATE program may be eligible to participate in GLADIATOR.

    ClinicalTrials.gov: NCT04607837
  • Navigating a path forward in EoE
    Phase 2 clinical trial evaluating the safety and efficacy of etrasimod in patients with eosinophilic esophagitis (EoE).

    ClinicalTrials.gov: NCT04682639
    Patient Trial Site
Clinical Trials
ULCERATIVE COLITIS
UC 52 UC 52
Phase 3
UC 12 UC 12
Phase 3
Phase 2
CROHN’S DISEASE
Phase 2/3
EOSINOPHILIC ESOPHAGITIS
Phase 2
ATOPIC DERMATITIS
Phase 3 Planning
ALOPECIA AREATA
Phase 2
Etrasimod is an investigational drug and is not currently approved for use by any health authority.
Retained Rights: Worldwide, excluding rights granted to Everest Medicines for Greater China and certain other Asian territories.